• Merck disclosed results from a global survey on canine allergic skin disease; findings have already been released, with no future presentation flagged.
• Owners and veterinarians reported persistent difficulty diagnosing causes, sustaining compliance, and finding treatments that work quickly without safety trade-offs.
• Therapy switching remained common, pointing to dissatisfaction with current options and a commercial opening for faster-acting, more targeted products.
• Veterinarians highlighted affordability as a key unmet need, signaling pricing pressure alongside demand for newer modalities.
• The survey also pointed to a treatment gap for younger dogs, supporting interest in products positioned for broader age eligibility.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260617911309) on June 17, 2026, and is solely responsible for the information contained therein.